Toggle navigation
Menu
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
73°
Search
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Local Weather
News
Sports
Entertainment
Calendar
Games
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Town & Gown
Subscribe
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
News releases from Optinose
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays
September 29, 2020
Improvement was observed across a broad range of measures including multiple symptoms and both general and disease-specific quality of life
Tickers
OPTN
From
PR Newswire
Optinose Announces FDA Approval of XHANCE™ (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps
September 18, 2017
Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food & Drug Administration (FDA) approved the Company’s New Drug Application (NDA) for XHANCE (previously...
From
Business Wire News Releases
OptiNose Raises $37 Million in Series D Funding Led by Fidelity
May 09, 2017
OptiNose, a commercial-stage ENT / Allergy specialty pharmaceutical company, today announced that it has closed a $37 million Series D financing led by Fidelity Management and Research Company with...
From
Business Wire News Releases
Michael F. Marino Joins OptiNose as Chief Legal Officer
February 09, 2017
OptiNose™ today announced the appointment of Michael F. Marino as Chief Legal Officer. Mr. Marino is a seasoned executive and legal advisor with more than 15 years of experience advising public and...
From
Business Wire News Releases
OptiNose Announces FDA Acceptance for Filing of the New Drug Application for OPN-375
January 31, 2017
OptiNose™ today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for the investigational new product OPN-375. OptiNose is seeking...
From
Business Wire News Releases
OptiNose Appoints Keith Goldan as Chief Financial Officer
January 26, 2017
OptiNose today announced the appointment of Keith A. Goldan as Chief Financial Officer (CFO). Mr. Goldan brings to the company more than 25 years of executive finance and operational leadership in...
From
Business Wire News Releases
CORRECTING and REPLACING OptiNose to Present at the 35th Annual J.P. Morgan Healthcare Conference
December 21, 2016
Please replace the release due to revisions to the company boilerplate.
From
Business Wire News Releases
New Research Highlights the Burden of Illness Suffered by Chronic Rhinosinusitis Patients
September 19, 2016
According to new research presented today at the American Rhinologic Society Annual Meeting, an estimated 28 million Americans are currently suffering from the symptoms of Chronic Rhinosinusitis (CRS)...
From
Business Wire News Releases
CORRECTING and REPLACING OptiNose Presents Data from Phase 3 Trials with Investigational Product Using Exhalation Delivery System Technology for Treatment in Patients with Chronic Rhinosinusitis (CRS)
September 16, 2016
In the original release, there were two instances (second bullet under NAVIGATE II and first bullet under EXHANCE-12) where dosage amounts of EDS-FLU read 371 µg twice daily; these should have read 372...
From
Business Wire News Releases
OptiNose Announces FDA Approval for ONZETRA™ Xsail™ (sumatriptan nasal powder), a New Treatment for Acute Migraine Using Bi-Directional™ Breath Powered® Technology
January 28, 2016
OptiNose, a privately-held specialty biopharmaceutical company, today announced that its licensing partner, Avanir Pharmaceuticals, Inc. has reported that the U.S. Food & Drug Administration (FDA)...
From
Business Wire News Releases
OptiNose to Present at the 34th Annual J.P. Morgan Healthcare Conference
December 17, 2015
OptiNose today announced that the company will present at the 34th annual J.P. Morgan Healthcare Conference. CEO Peter Miller will discuss the Company's recent milestones, pipeline and strategy for...
From
Business Wire News Releases
OptiNose Closes New Round of Financing
October 06, 2015
OptiNose, a specialty biopharmaceutical company, announced today that it has closed a new round of financing providing up to $30M in additional capital. Since completing its previous financing round in...
From
Business Wire News Releases
OptiNoseTM Announces Positive Results of Second Phase III Pivotal Trial for OPN-375
September 24, 2015
OptiNose today announced positive results from a second phase III pivotal trial, NAVIGATE I. This follows and helps both to confirm and support the positive results from a first pivotal trial, NAVIGATE...
From
Business Wire News Releases
OptiNose Announces Positive Results of Phase III Trial for OPN-375
June 24, 2015
From
Business Wire News Releases
OptiNose to Present at Innovations in Healthcare Executive Forum
March 30, 2015
From
Business Wire News Releases
OptiNose to Present at Nasal and Respiratory Drug Delivery Conferences
March 19, 2015
From
Business Wire News Releases
OptiNose to Present at the 35th Annual Cowen Healthcare Conference
February 23, 2015
From
Business Wire News Releases
OptiNose to Present at the 33rd Annual J.P. Morgan Healthcare Conference
December 18, 2014
From
Business Wire News Releases
OptiNose Announces Publication of Pivotal Phase III Results for Investigational Migraine Treatment Developed by OptiNose Using Bi-Directional™ Breath Powered™ Technology
October 31, 2014
From
Business Wire News Releases
OptiNose Completes Series C-1 Financing
August 04, 2014
Current Investors and Management Increase Support for OptiNose and the Company's Breakthrough New Product, OPN-375
From
PR Newswire
OptiNose Expands Senior Management Team with Three Key Appointments in Core Business Areas of Operations, Regulatory Affairs and Commercialization
June 12, 2014
From
PR Newswire
OptiNose Announces Positive Results of COMPASS: A Head-to-Head Comparison of a New Migraine Treatment Using Bi-Directional™ Breath Powered™ Technology (AVP-825) versus Oral Sumatriptan
June 10, 2014
AVP-825, Using OptiNose's Patented Bi-Directional™ Breath Powered™ Technology for Intranasal Delivery of Low-dose Sumatriptan, Demonstrates Greater Reduction in Migraine Pain Compared to the Highest...
From
PR Newswire
OptiNose Announces FDA Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migraine
March 27, 2014
AVP-825 relies on novel closed palate Breath Powered™ drug delivery technology
From
PR Newswire
OptiNose Announces First Patient Enrolled in Phase III Study of Sumatriptan Powder Delivered Intranasally with Innovative Bi-directional Device
February 09, 2012
From
Business Wire News Releases
New Hope for Migraine Sufferers: Optinose Nasal Delivery of Sumatriptan Proves as Effective as Invasive Subcutantaneous Injection
April 17, 2008
From
Business Wire News Releases
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
